Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs PayPal Holdings, Inc. (PYPL) Price & Performance

Citius Pharmaceuticals IncTrade
PayPal Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs PayPal Holdings, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while PayPal Holdings, Inc. trades at $58.84 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 2697.8× Citius Pharmaceuticals Inc's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRPYPL
Market Cap
$18.73M$50.53B
Sector
HealthFinancials
52-Week High
$1.82$76.13
52-Week Low
$0.48$39.08
Enterprise Value
$14.95M$52.68B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

PayPal Holdings, Inc.

PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.

PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About PayPal Holdings, Inc.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.

Read more on PYPL